Clinical relevance of epigenetic dysregulation in chronic kidney disease-associated cardiovascular disease

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1663-1671

  Zawada, Adam M ^a   Rogacev, Kyrill S ^a   Heine, Gunnar H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Arteriosclerosis; Cardiovascular disease; Chronic kidney disease; DNA methylation; Epigenetics

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; ESTROGEN RECEPTOR ALPHA GENE; ESTROGEN RECEPTOR BETA GENE; GENETIC ASSOCIATION; GENETIC REGULATION; HISTONE MODIFICATION; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DNA METHYLATION; EPIGENETICS;

CARDIOVASCULAR DISEASES; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84884520543     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft042     Document Type: Review

References (60)

1. Herzog CA, Asinger RW, Berger AK et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572-586
2. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324
3. Gluckman PD, Hanson MA, Cooper C et al. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008; 359: 61-73
4. Bechtel W, McGoohan S, Zeisberg EM et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16: 544-550
5. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92
6. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150: 12-27
7. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med 2012; 367: 647-657
8. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143-153
9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232
10. Bird A. Perceptions of epigenetics. Nature 2007; 447: 396-398
11. Lorenzen JM, Martino F, Thum T. Epigenetic modifications in cardiovascular disease. Basic Res Cardiol 2012; 107: 245
12. Dwivedi RS, Herman JG, McCaffrey TA et al. Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int 2011; 79: 23-32
13. Dressler GR. Epigenetics, development, and the kidney. J Am Soc Nephrol 2008; 19: 2060-2067
14. Miranda TB, Jones PA. DNA methylation: the nuts and bolts of repression. J Cell Physiol 2007; 213: 384-390
15. Castro R, Rivera I, Struys EA et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 2003; 49: 1292-1296
16. Baccarelli A, Wright R, Bollati V et al. Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology 2010; 21: 819-828
17. Sharma P, Kumar J, Garg G et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol 2008; 27: 357-365
18. Kim M, Long TI, Arakawa K et al. DNA methylation as a biomarker for cardiovascular disease risk. PLoS One 2010; 5: e9692
19. Castillo-Diaz SA, Garay-Sevilla ME, Hernandez-Gonzalez MA et al. Extensive demethylation of normally hypermethylated CpG islands occurs in human atherosclerotic arteries. Int J Mol Med 2010; 26: 691-700
20. Hiltunen MO, Turunen MP, Hakkinen TP et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med 2002; 7: 5-11
21. Laukkanen MO, Mannermaa S, Hiltunen MO et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol 1999; 19: 2171-2178
22. Lund G, Andersson L, Lauria M et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem 2004; 279: 29147-29154
23. Ekstrom TJ, Stenvinkel P. The epigenetic conductor: a genomic orchestrator in chronic kidney disease complications? J Nephrol 2009; 22: 442-449
24. Stenvinkel P, Ekstrom TJ. Epigenetics and the uremic phenotype: a matter of balance. Contrib Nephrol 2008; 161: 55-62
25. Stenvinkel P, Ekstrom TJ. Epigenetics-a helpful tool to better understand processes in clinical nephrology? Nephrol Dial Transplant 2008; 23: 1493-1496
26. Post WS, Goldschmidt-Clermont PJ, Wilhide CC et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999; 43: 985-991
27. Ying AK, Hassanain HH, Roos CM et al. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. Cardiovasc Res 2000; 46: 172-179
28. Kim J, Kim JY, Song KS et al. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and invitro vascular senescence. Biochim Biophys Acta 2007; 1772: 72-80
29. Zhu S, Goldschmidt-Clermont PJ, Dong C. Inactivation of monocarboxylate transporter MCT3 by DNA methylation in atherosclerosis. Circulation 2005; 112: 1353-1361
30. Zawadzki C, Chatelain N, Delestre M et al. Tissue factor pathway inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. Atherosclerosis 2009; 204: e4-14
31. Ingrosso D, Perna AF. Epigenetics in hyperhomocysteinemic states. A special focus on uremia. Biochim Biophys Acta 2009; 1790: 892-899
32. Perna AF, Ingrosso D, Violetti E et al. Hyperhomocysteinemia in uremia-a red flag in a disrupted circuit. Semin Dial 2009; 22: 351-356
33. Ingrosso D, Cimmino A, Perna AF et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003; 361: 1693-1699
34. Stenvinkel P, Karimi M, Johansson S et al. Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease? J Intern Med 2007; 261: 488-499
35. Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 609-614
36. Au-Yeung KK, Woo CW, Sung FL et al. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 2004; 94: 28-36
37. Poddar R, Sivasubramanian N, DiBello PM et al. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001; 103: 2717-2723
38. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-2081
39. Bienvenu T, Ankri A, Chadefaux B et al. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res 1993; 70: 123-129
40. Nanayakkara PW, Kiefte-de Jong JC, Stehouwer CD et al. Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease. Nephrol Dial Transplant 2008; 23: 2586-2592
41. Geisel J, Schorr H, Heine GH et al. Decreased p66Shc promoter methylation in patients with end-stage renal disease. Clin Chem Lab Med 2007; 45: 1764-1770
42. Bostom AG, Carpenter MA, Kusek JW et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011; 123: 1763-1770
43. Heinz J, Kropf S, Domrose U et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010; 121: 1432-1438
44. Jamison RL, Hartigan P, Kaufman JS et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-1170
45. Wrone EM, Hornberger JM, Zehnder JL et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420-426
46. Zoungas S, McGrath BP, Branley P et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006; 47: 1108-1116
47. Green TJ, Skeaff CM, McMahon JA et al. Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations. Br J Nutr 2010; 103: 1629-1634
48. Kerins DM, Koury MJ, Capdevila A et al. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 2001; 74: 723-729
49. Liu C, Wang Q, Guo H et al. Plasma S-adenosylhomocysteine is a better biomarker of atherosclerosis than homocysteine in apolipoprotein E-deficient mice fed high dietary methionine. J Nutr 2008; 138: 311-315
50. Jabs K, Koury MJ, Dupont WD et al. Relationship between plasma S-adenosylhomocysteine concentration and glomerular filtration rate in children. Metabolism 2006; 55: 252-257
51. Garibotto G, Valli A, Anderstam B et al. The kidney is the major site of S-adenosylhomocysteine disposal in humans. Kidney Int 2009; 76: 293-296
52. Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 662-668
53. Jang TJ, Kim DI, Shin YM et al. p16(INK4a) Promoter hypermethylation of non-tumorous tissue adjacent to gastric cancer is correlated with glandular atrophy and chronic inflammation. Int J Cancer 2001; 93: 629-634
54. Kang GH, Lee HJ, Hwang KS et al. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 2003; 163: 1551-1556
55. Hodge DR, Xiao W, Clausen PA et al. Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem 2001; 276: 39508-39511
56. Francia P, delli Gatti C, Bachschmid M et al. Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation 2004; 110: 2889-2895
57. Migliaccio E, Giorgio M, Mele S et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999; 402: 309-313
58. Sapienza C, Lee J, Powell J et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics 2011; 6: 20-28
59. Zawada AM, Rogacev KS, Hummel B et al. Super TAG Methylation-Specific Digital Karyotyping (SMSDK) reveals uremiainduced epigenetic dysregulation of atherosclerosis-related. Circ Cardiovasc Genet. 2012; 5: 611-620.
60. Napoli C, Crudele V, Soricelli A et al. Primary prevention of atherosclerosis: a clinical challenge for the reversal of epigenetic mechanisms? Circulation 2012; 125: 2363-2373